Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Bertsch, Uta  [Clear All Filters]
2024
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, et al. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Lancet Haematol. 2024;11(2):e101-e113.
2023
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, et al. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. Front Immunol. 2023;14:1286700.
2022
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase . Lancet Haematol. 2022;9(11):e810-e821.
2016
Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, et al. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget. 2016.
Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab M-S, Hose D, Ho AD, et al. Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology. 2016;5(5):e1139662.